Current development and introduction of hemoglobin-based blood substitutes
- Authors: Selivanov EA1, Pshenkina NN2, Murzina EV3, Sofronov GA2, Khanevich MD1, Sarychev VA4
-
Affiliations:
- Russian Research Institute for Hematology and Transfusiology of Health Ministry of Russian Federation, St. Petersburg
- Research Institute for Experimental Medicine of the Northwest Branch of Russian Academy of Medical Sciences, St. Petersburg
- S.M. Kirov Military Medical Academy, St. Petersburg
- Gelenpol, Ltd., Obninsk, Kaluga region
- Issue: Vol 11, No 2 (2011)
- Pages: 49-60
- Section: Articles
- Published: 15.06.2011
- URL: https://journals.eco-vector.com/MAJ/article/view/10004
- DOI: https://doi.org/10.17816/MAJ11249-60
- ID: 10004
Cite item
Full Text
Abstract
Full Text
About the authors
E A Selivanov
Russian Research Institute for Hematology and Transfusiology of Health Ministry of Russian Federation, St. Petersburg
N N Pshenkina
Research Institute for Experimental Medicine of the Northwest Branch of Russian Academy of Medical Sciences, St. Petersburg
Email: p5hcnkina@mail.ru
E V Murzina
S.M. Kirov Military Medical Academy, St. Petersburg
G A Sofronov
Research Institute for Experimental Medicine of the Northwest Branch of Russian Academy of Medical Sciences, St. Petersburg
M D Khanevich
Russian Research Institute for Hematology and Transfusiology of Health Ministry of Russian Federation, St. Petersburg
V A Sarychev
Gelenpol, Ltd., Obninsk, Kaluga region
References
- Воробьев С.И. Перфторуглеродные эмульсии I и II поколения // Хим.-фарм. журн. 2009. Т. 43. № 4. С. 30^10.
- Голубев А.М., Белоярцев Ф.Ф., Васильев А.Э., Покровский Ю.Э. Реакции биологических систем при замещении крови эмульсиями фторуглеродов. М.: ТЕМС, 1993.
- Дьяконов А.Н., Бурданов А.П., Корик В.Е., Коновалов С.В. Применение геленпола при операциях на толстой кишке // Применение инфузионных антиги- поксантов и искусственных переносчиков кислорода в хирургии: Сб. науч. тр. СПб., 1999. С. 16-18.
- Иваницкий Г.Р. Биофизика на пороге нового тысячелетия: перфторуглеродныс среды и газотранспортные кровезаменители // Биофизика. 2001. Т. 46. №1. С. 5-33.
- Корик В.Е. Применение кровезаменителя-перенос- чика кислорода на основе модифицированного гемоглобина при лечении больных с тяжелой кровопотерей: автореф. дис.. канд. мед. наук. СПб., 2000.
- Кузнецова Н.П., Гудкин Л.Р., Мишаева Р.Н. Способ получения полигемоглобина с повышенной кислородтранспортной эффективностью / Патент RU 2132687, 1999.
- Кузнецова Н.П., Гудкин Л.Р., Селиванов Е.А. и др. Кровезаменитель-переносчик кислорода, состав для его получения и способ получения полимерного модифицированного гемоглобина / Патент RU 2162707, 2001.
- Самсонов Г.В. и др. Солевой раствор полимерного гемоглобина / Патент SU 183354A3, 1992.
- Селиванов Е.А., Быстрова И.М., Ханевич М.Д., Парашин М.Е. Экспериментальное и клиническое изучение кровезаменителя-переносчика кислорода на основе модифицированного гемоглобина // Физиологически активные вещества на основе перфторуглеродов в военной медицине: Сб. матер, науч. конф. СПб., 1997. С. 95-96.
- Селиванов Е.А., Софронов Г. А., Ханевич М.Д. и др. Эффективность применения перфторана в хирургической практике // Трансфузиология. 2008. № 2. С. 78-88.
- Селиванов Е.А., Софронов Г.А., Ханевич М.Д., Скрябин О.Н. Возможности применения модифицированного гемоглобина в хирургии // Трансфузиология. 2008. Т. 9. № 2. С. 68-77.
- Склифас А.Н., Шехтман Д.Г., Образцов В.В. и др. Механизмы распределения и выведения перфторуглеродов при многократных введениях // Биофизика. 1998. Т. 43. № 1.С. 171-176.
- Софронов Г.А., Селиванов Е.А., Ханевич М.Д. Переносчики кислорода: состояние проблемы и перспективы развития // Применение инфузионных антигипоксантов и искусственных переносчиков кислорода в хирургии: Сб. науч. тр. СПб., 1999. С. 75-85.
- Сухоруков В.П., Рагимов А.А., Пушкин С.Ю. и др. Перфторан - перфторуглеродный кровезаменитель с газотранспортной функцией: пособие для врачей. 2-е изд., перераб. и доп. М., 2008.
- Филатов Ф.П. Вирусная безопасность переливания крови // Природа. 2005. № 3. URL: http://vivovoco. rsl.ru/VV/JOURNAL/NATURE/03 05/VIRUS.HTM
- Ханевич М.Д., Софронов Г.А., Селиванов Е.А., Корик В.Е. Применение искусственного переносчика кислорода на основе модифицированного гемоглобина у больных с гастродуоденальными кровотечениями // Вести, хирургии им. И.И. Грекова. 2000. Т. 159. №6. С. 51-54.
- Шевченко Ю.Л., Шабалин В.Н., Зарнвчацкий М.Ф., Селиванов Е.А. Руководство по общей и клинической трансфузиологии. СПб.: Фолиант, 2003.
- Ярочкин В.С., Кочемасов В.В. Гемодилюция. Настоящее и будущее. М., 1997.
- Alayash АЛ. Redox and Radical Reactions of Hemoglobin Solutions: Toxicities and Protective Strategies // Blood Substitutes / Ed. by R. Winslow. San Diego: Academic Press, 2006. P. 197-205.
- Amberson W.R. Blood substitutes // Biol. Rev. 1937. Vol. 12. P. 48-85.
- Benesch R.E., Benesch R., Rcnthal R.D., Maeda N. Affinity labeling of the polyphosphate binding site of hemoglobin // Biochemistry. 1972. ѴЫ. 11. № 19. P. 3576-3582.
- Bjorkholm M., Fagrell B., Przybelski R. et al. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human Hb modified with maleimide-ac- tivated polyethylene glycol // Haematologica. 2005. Vol. 90. № 4. P. 505-515.
- Blood substitutes / Ed. by R. Winslow. San Diego: Academic Press, 2006.
- Carmichael F.J., АН A.C., Campbell J.A. et al. A phase I study of oxidized raffinose cross-linked human hemoglobin // Crit. Care Med. 2000. Vol. 28. № 7. P. 2283- 2292.
- Carson J.L., Noveck H., Berlin J.A., Gould S.A. Mortality and morbidity' in patients with very low postoperative Hb levels who decline blood transfusion // Transfusion. 2002. Vol. 42. № 7. P. 812-818.
- Chang T.M. A nanobiotechnologic therapeutic that transport oxygen and remove oxygen radicals: for stroke, hemorrhagic shock and related conditions // Artificial cells: biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation and cell/stem cell therapy / Ed. by T.M. Chang. Singapore: World Science Publisher, 2007. P. 62-92.
- Chang T.M. Nanobiotechnology for Hemoglobin-based blood substitutes // Crit. Care Clin. 2009. Vol. 25. № 2. P. 373-382.
- Cheng D.C. Safety and efficacy of o-raffinose cross- linked human hemoglobin (Hemolink) in cardiac surgery // Can. J. Anaesth. 2001. Vol. 48. № 4 (Suppl.) S. 41^18.
- Cohn C.S., Cushing M.M. Oxygen therapeutics: per- fluorocarbons and blood substitute safety // Crit. Care Clin. 2009. Vol. 25. № 2. P. 399-414.
- D’Agnillo F., Chang T.M. Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties //Nat. Biotechnol. 1998. Vol. 16. № 7. P.667-671.
- Drobin D., Kjellstrom B.T., Malm E. et al. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4) // J. Appl. Physiol. 2004. ѴЫ. 96. № 5. P. 1843-1853.
- Epstein J.S., Holmberg J.A. Progress in monitoring blood safety // Transfusion. 2010. Vol. 50. № 7. P. 1408-1412.
- Gould S.A., Moore E.E., Hoyt D.B. et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery //J. Am. Coll. Surg. 1998. Vol. 187. №2. P. 113-120.
- Gould S.A., Moore E.E., Hoyt D.B. et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable // J. Am. Coll. Surg. 2002. Vol. 195. № 4. P. 445^452.
- Gould S.A., Moore E.E., Moore F.A. et al. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery // J. Trauma. 1997. Vol. 43. № 2. P. 325-331.
- Greenburg A.G., Kim H.W. Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery // J. Am. Coll. Surg. 2004. Vol. 198. № 3. P. 373-385.
- Henkel-Honke T., Oleck M. Artificial oxygen carriers: a current review // AANA. 2007. Vol. 75. № 3. P. 205- 211.
- Hill S.E., Gottschalk L.I., Grichnik K. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery // J. Cardio- thorac. Vase. Anesth. 2002. Vol. 16. № 6. P. 695-702.
- Hoffman S.J., Looker D.L., Roehrich J.M. et al. Expression of fully functional tetrameric human hemoglobin in Escherichia coli // Proc. Natl. Acad. Sci. USA. 1990. Vol. 87. № 21. P. 8521-8525.
- Izumi Y., Sakai H., Kose T. et al. Evaluation of the capabilities of a hemoglobin vesicle as an artificial oxygen carrier in a rat exchange transfusion model // ASAIO. 1997. Vol. 43. № 4. P. 289-297.
- Jahr J.S., Varma N. PolyHeme. Northfield Laboratories // IDrugs. 2004. Vol. 7. № 5. P. 478-482.
- Jahr J.S., Weeks D.L., Desai P. et al. Does OxyVita, a new-generation hemoglobin based oxygen carrier, or Oxyglobin acutely interfere with coagulation compared with normal saline or 6% hetastarch? II J. Cardiotho- rac. Vas. Anesth. 2008. Vol. 22. № 1. P. 34-38.
- Jia Y., Alayash A.l. Effects of cross-linking and zero- link polymerization on oxygen transport and redox chemistry of bovine hemoglobin // Biochim. Biophys. Acta. 2009. Vol. 1794. № 8. P. 1234-1242.
- Kasper S.M., Walter M., Grime F. et al. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery //Anesth. Analg. 1996. Vol. 83. № 5. P. 921-927.
- Kerger H., Tsai A.G., Saltzman D.J. et al. Fluid resuscitation with 02 vs. non-02 carriers after 2 h of hemorrhagic shock in conscious hamsters //Am. J. Physiol. 1997. Vol. 272. №> 1 (Pt. 2). H525-537.
- Kemer T., Aiders O., Veit S. et al. DCL-Hb for trauma patients with severe hemorrhagic shock: the European “On-Scene” multicenter study // Intensive Care Med. 2003. Vol. 29. № 3. P. 378-385.
- Kim H.W., Greenburg A.G. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status // Artif. Organs. 2004. Vol. 28. № 9. P. 813- 828.
- Kim H.W, Greenburg A.G. Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others // Artif. Cells Blood Substit. Immobil. Biotechnol. 2006. Vol. 34. № 6. P. 537-550.
- LaMuraglia G.M., O’Hara P.J., Baker W.H. et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution // J. Vase. Surg. 2000. Vol. 31. № 2. P. 299-308.
- Lamy M.L., Daily E.K., Brichant J.F. et al. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery//Anesthesiology. 2000. Vol. 92. № 3. P. 646- 656.
- Levy J.H., Goodnough L.T., Greilich P.E. et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial // J. Thorac. Cardiovasc. Surg. 2002. ѴЫ. 124. № 1. P. 35- 42.
- Loeb A.L., McIntosh L.J., Raj N.R., Longnecker D.E. Resuscitation after hemorrhage using recombinant human hemoglobin (rHbl.l) in rats: effects on nitric oxide and prostanoid systems // Crit. Care Med. 1998. Vol. 26. №6. P. 1071-1080.
- Looker D., Abbott-Brown D., Cozart P. et al. A human recombinant haemoglobin designed for use as a blood substitute // Nature. 1992. Vol. 356. № 6366. P. 258- 260.
- Lowe K.C. Genomics and blood substitutes for 21st century Europe (“EuroBloodSubstitutes”) //Artif. Cells Blood Substit. Immobil. Biotechnol. 2006. Vol. 34. N 6. P. 589-599.
- Lowenstein C.J., Dinerman J.L., Snyder S.H. Nitric oxide: a physiologic messenger//Ann. Intern. Med. 1994. Vol. 120. № 3. P. 227-237.
- Malhotra A.K., Kelly M.E., Miller P.R. et al. Resuscitation with a novel hemoglobin-based oxygen carrier in a Swine model of uncontrolled perioperative hemorrhage // J. Trauma. 2003. Vol. 54. № 5. P. 915-924.
- Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology // Pharmacol. Rev. 1991. Vol. 43. № 2. P. 109-142.
- Moore E.E., Moore F.A., Fabian T.C. et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial // J. Am. Coll. Surg. 2009. Vol. 208. № 1. P. 1-13.
- Moskowitz D.M., McCullough J.N., Shander A. et al. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective? // Ann. Thorac. Surg. 2010. Vol. 90. № 2. P. 451-458.
- Murphy G.J., Reeves B.C., Rogers C.A. et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery // Circulation. 2007. Vol. 116. № 22. P. 2544- 2552.
- Nakaki T. Physiological and clinical significance of nitric oxide // Keio J. Med. 1994. Vol. 43. № 1. P. 15-26.
- Natanson C., Kern S.J., Lurie P. et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis // JAMA. 2008. Vol. 299. № 19. P.2304-2312.
- Ness P.M., Cushing M.M. Oxygen therapeutics. Pursuit of an alternative to the donor red blood cell //Arch. Pathol. Lab. Med. 2007. Vol. 131. JNe 5. P. 734-741.
- Ning J., Wong L.T., Christoff B. et al. Haemodynamic response following a 10% topload infusion of Hemolink™ in conscious, anaesthetized and treated spontaneously hypertensive rats // Transfus. Med. 2000. Vol. 10. № l.P 13-22.
- Olofsson C., Ahl T., Johansson T. et al. A multicenter clinical study of the safety and activity of maleimide- polyethylene glycol Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery //Anesthesiology. 2006. Vol. 105. № 6. P 1153-1163.
- Pearce L.B., Gawryl M.S., Rentko V.T. et al. HBOC- 201 (Hemoglobin GIutamer-250 (Bovine), Hemo- pure®): Clinical studies // Blood substitutes / Ed. by R. Winslow. San Diego: Academic press, 2006. P. 437-450.
- Pirie E., Green J. A framework to support safe blood transfusion practice // Nurs. Stand. 2010. Vol. 24. № 48. P. 35-40.
- Powanda D.D., Chang T.M. Cross-linked polyhemo- globin-superdioxide dismutase-catalase supplies oxygen without causing blood-brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion // Art. Cells Blood Subsstit. Im- mobil. Biotechnol. 2002. Vol. 30. № 1. P. 25-42.
- Riess J.G. Oxygen carriers (“blood substitutes”) - raison d’etre, chemistry and some physiology // Chem. Rev. 2001. Vol. 101. Na 9. P. 2797-2920.
- Saezler R.K., Arfors K.E., Tuma R.F. et al. Polynitrox- ylated hemoglobin-based oxygen carrier: inhibition of free radical induced microcirculatory dysfunction // Free Radic. Biol. Med. 1999. Vol. 27. № 1-2. P. 1-6.
- Sakai H., Horinouchi H., Yamamoto M. et al. Acute 40 percent exchange-transfusion with hemoglobin-vesicles (HbV) suspended in recombinant human serum albumin solution: Degradation of HbV and erythropoi- esis in a rat spleen for 2 weeks // Transfusion. 2006. Vol. 46. № 3. P. 339-347.
- Sakai H., Masada Y., Horinouchi H. et al. Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats // Crit. Care Med. 2004. Vol. 32. № 2. P. 539-545.
- Sakai H., Sou K., Horinouchi H. et al. Hemoglobin- vesicles as artificial oxygen carriers: present situation and future visions // J. Intern. Med. 2008. Vol. 263. № l.P. 4-15.
- Sakai H., Sou K., Horinouchi H. et al. Review of hemoglobin-vesicles as artificial oxygen carriers // Artif. Organs. 2009. Vol. 33. № 2. P. 139-145.
- Sakai H., Sou K., Tsuchida E. Hemoglobin-vesicles as an artificial oxygen carrier//Methods Enzymol. 2009. Vol. 465. P. 363-384.
- Sakai H., Takeoka S., Park S.I. et al. Surface modification of hemoglobin vesicles with poly(ethylene glycol) and effects on aggregation, viscosity, and blood flow during 90% exchange transfusion in anesthetized rats // Bioconjug. Chem. 1997. ѴЫ. 8. № 1. P. 23-30.
- Sakai H., Tomiyama K., Sou K. et al. Polyethylene glycol)-conjugation and deoxygenation enable longterm preservation of hemoglobin-vesicles as oxygen carriers in a liquid state // Bioconjug. Chem. 2000. Vol. 11. N9 3. P.425-432.
- Savitsky J.P., Doczi J., Black J., Arnold J.D. Clinical safety trial of stroma-free hemoglobin // Clin. Pharmacol. Ther. 1978. Vol. 23. № 1. P 73-80.
- Schubert A., Przybelski R.J., Eidt J.F. et al. Diaspirin- crosslinked hemoglobin reduces blood transfusion in noncardiac surgery: a multicenter, randomized, controlled, double-blinded trial // Anesth. Analg. 2003. Vol. 97. № 2. P. 323-332.
- Selivanov E.A., Kochetygov N.L., Bistrova I.M. et al. Study of polymerized hemoglobin in experiment // Artif. Cells Blood Substit. Immobil. Biotechnol. 1994. Vol. 22. № 5. P. 156.
- Siegel J.H., Fabian M., Smith J.A., Costantino D. Use of recombinant hemoglobin solution in reversing lethal hemorrhagic hypovolemic oxygen debt shock // J. Trauma. 1997. Vol. 42. № 2. P. 199-212.
- Simoni J. Artificial oxygen carriers: scientific and biotechnological points of view //Artif. Organs. 2009. Vol. 33. № 2. P. 92-96.
- Simoni J. Endothelial cell response to hemoglobin based oxygen carriers. Is the attenuation of pathological reactions possible? // Artificial Oxygen Carrier. Its Front Line / Kobayashi K., Tsuchida E., Horinouchi H. eds. Tokyo: Springer-Verlag, 2005. P. 25-75.
- Simoni J., Simoni G., Moeller J.F. Intrinsic toxicity of hemoglobin: how to counteract it // Artif. Organs. 2009. Vol. 33. № 2. P 100-109.
- Simoni J., Villanueva-Meyer J., Simoni G. et al. Control of oxidative reactions of hemoglobin in the design of blood substitutes: role of the ascorbate-glutathione antioxidant system //Artif. Organs. 2009. Vol. 33. №2. P. 115-126.
- Sloan Е.Р., Koenigsberg М., Gens D. et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial // JAMA. 1999. ѴЫ. 282. № 19. P. 1857-1864.
- Sou K., Klipper R., Goins B. et al. Circulation kinetics and organ distribution of Hb vesicles developed as a red blood cell substitute // J. Pharmacol. Exp. Ther. 2005. Vol. 312. P.702-709.
- Spahn D.R., Kocian R. Artificial 0, carriers: status in 2005 // Curr. Pharm. Des. 2005. Vol. 11. № 31. P.4099-4114.
- Sprung J., Kindscher J.D., Wahr J.A. et al. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: Results of a multicenter, randomized single-blind study //Anesth. Analg. 2002. Vol. 94. № 4. P. 799-808.
- Stowell C.P., Levin J., Spiess B.D., Winslow R.M. Progress in the development of RBC substitutes // Transfusion. 2001. Vol. 41. № 2. P. 287-299.
- Strauss R.G. Blood banking issues pertaining to neonatal red blood cell transfusions // Transfus. Sci. 1999. Vol. 21. № 1. P.7-19.
- Tsai A.G., Vandegriff K.D., Intaglietta M., Winslow R.M. Targeted O, delivery by low-PJ0 hemoglobin: a new basis for O, therapeutics //Am. j. Physiol. 2003. Vol. 285. № 4. P. 1411-1419.
- Vamvakas E.C., Taswell H.F. Epidemiology of blood transfusion // Transfusion. 1994. Vol. 34. № 6. P. 464- 470.
- Vandegriff K., Winslow R.M. Hemospan: design principles for a new class of oxygen therapeutic // Artif. Organs. 2009. Vol. 33. № 2. P. 133-138.
- Vandegriff K.D., Malavalli A., Wooldridge J. et al. MP4, a new nonvasoactive PEG-Hb conjugate // Transfusion. 2003. Vol. 43. №4. P. 509-516.
- von Dobschuetz E., Hutter J., Hoffmann T., Messmer K. Recombinant human hemoglobin with reduced nitric oxide-scavenging capacity restores effectively pancreatic microcirculatory disorders in hemorrhagic shock //Anesthesiology. 2004. Vol. 100. № 6. P. 1484-1490.
- Winslow R. Current status of blood substitute research: towards a new paradigm // J. Intern. Med. 2003. Vol. 253. № 5. P. 508-517.
- Winslow R.M., Chapman K.W., Vandegriff K.D., Young M. Hemospan® (MP4), A human hemoglobin modified with maleimide-polyethylene glycol // Blood Substitutes / Ed. by R. Winslow. San Diego: Academic Press, 2006. P. 470-482.
- Winslow R.M., Lohman J., Malavalli A., Vandegriff K.D. Comparison of PEG-modified albumin and hemoglobin in extreme hemodilution in the rat // J. Appl. Physiol. 2004. Vol. 97. № 4. P. 1527-1534.
- WongN., Chang T.M. Polyhemoglobin-fibrinogen: a novel oxygen carrier with platelet-like properties in a hemodiluted setting //Art. Cells Blood Substit. Im- mobil. Biotechnol. 2007. Vol. 35. № 5. P. 481-489.
- Yazer M.H., Triulzi D.J. Receipt of older RBCs does not predispose D-negative recipients to anti- D alloimmunization //Am. J. Clin. Pathol. 2010. Vol. 134. №3. P.443-447.
- Young M.A., Lohman J., Malavalli A. et al. Hemospan improves outcome in a model of peri-operative hemodilution and blood loss in the rat: comparison with hydroxyethyl starch // J. Cardiothorac. Vase. Anesth. 2009. Vol. 23. № 3. P. 339-347.
- Young M.A., Riddez L., Kjellstrom B.T. et al. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine // Crit. Care Med. 2005. Vol. 33. № 8. P. 1794-1804.
- Zhu X., Chu W., Wang F. et al. Variations in dominant antigen determinants of glutaraldehyde polymerized human, bovine and porcine hemoglobin // Art. Cells Blood Substit. Immobil. Biotechnol. 2007. Vol. 35. № 5. P. 518-532.